List view / Grid view

Ian Glassford (Abenza)

 

article

Antibody Drug Conjugates: windows of opportunity

4 July 2023 | By , ,

This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…